A Food and Drug Administration advisory committee Tuesday recommended that the agency withdraw approval of the blockbuster cancer drug Avastin for treating breast cancer. The decision would not affect the manufacturer's ability to market the drug for treating colon, lung and other cancers.
Avastin contributes annual sales of about $6 billion to its manufacturer, Roche, with about a sixth of that from sales for breast cancer.
